Short Interest in Sensus Healthcare, Inc. (NASDAQ:SRTS) Expands By 1,311.0%

Sensus Healthcare, Inc. (NASDAQ:SRTS) saw a significant growth in short interest in the month of May. As of May 15th, there was short interest totalling 437,400 shares, a growth of 1,311.0% from the April 30th total of 31,000 shares. Currently, 3.3% of the shares of the company are short sold. Based on an average daily trading volume, of 513,200 shares, the days-to-cover ratio is presently 0.9 days.

Insider Activity at Sensus Healthcare

In other Sensus Healthcare news, Director John Heinrich sold 4,773 shares of the company’s stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $5.95, for a total value of $28,399.35. Following the completion of the transaction, the director now directly owns 75,167 shares in the company, valued at $447,243.65. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 11.10% of the stock is currently owned by company insiders.

Institutional Trading of Sensus Healthcare

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Creekmur Asset Management LLC purchased a new position in Sensus Healthcare during the fourth quarter worth approximately $83,000. Hillsdale Investment Management Inc. purchased a new position in Sensus Healthcare during the first quarter worth approximately $155,000. Sachetta LLC purchased a new position in Sensus Healthcare during the fourth quarter worth approximately $247,000. Finally, Perritt Capital Management Inc. boosted its position in Sensus Healthcare by 5.0% during the third quarter. Perritt Capital Management Inc. now owns 105,586 shares of the company’s stock worth $292,000 after purchasing an additional 5,000 shares in the last quarter. 25.30% of the stock is owned by institutional investors and hedge funds.

Sensus Healthcare Stock Up 4.3 %

Shares of NASDAQ SRTS traded up $0.23 during mid-day trading on Wednesday, reaching $5.64. 168,142 shares of the company were exchanged, compared to its average volume of 393,351. The stock has a market cap of $92.46 million, a price-to-earnings ratio of 19.45 and a beta of 0.92. Sensus Healthcare has a 1 year low of $1.79 and a 1 year high of $6.55. The firm has a 50-day moving average of $4.15 and a 200 day moving average of $3.47.

Sensus Healthcare (NASDAQ:SRTS) last announced its earnings results on Thursday, May 9th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.18. The company had revenue of $10.66 million for the quarter, compared to analyst estimates of $4.33 million. Sensus Healthcare had a return on equity of 9.76% and a net margin of 14.70%. During the same period in the prior year, the company posted ($0.12) EPS. On average, equities analysts forecast that Sensus Healthcare will post 0.29 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on SRTS shares. Maxim Group boosted their target price on shares of Sensus Healthcare from $7.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, May 10th. HC Wainwright increased their price objective on shares of Sensus Healthcare from $8.00 to $10.00 and gave the company a “buy” rating in a research report on Monday, May 13th.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.